MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-15-2026
NanoVibronix Net Debt 2011-2026 | NAOV
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt NanoVibronix
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.11 M | -636 K | - | - | - | -7.11 K | -1.34 M | -896 K | -4.36 M | -106 K | -1.61 M | 4.53 M | 3.01 M | 1.84 M | 559 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.53 M | -4.36 M | -260 K |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AdaptHealth Corp.
AHCO
|
1.64 B | $ 13.17 | 0.42 % | $ 1.78 B |  USA |
 |
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | USA |
 |
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | USA |
 |
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | USA |
 |
Delcath Systems
DCTH
|
-42.5 M | $ 10.75 | 3.56 % | $ 385 M | USA |
 |
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | USA |
 |
Second Sight Medical Products
EYES
|
2.62 M | - | -0.97 % | $ 54.4 M | USA |
 |
Electromed
ELMD
|
-10.5 M | $ 25.75 | 0.16 % | $ 218 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
Helius Medical Technologies
HSDT
|
-5.12 M | $ 2.11 | 3.19 % | $ 1.28 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 3.48 | 4.82 % | $ 130 M |  France |
 |
Inspire Medical Systems
INSP
|
-433 M | $ 57.07 | 1.66 % | $ 1.68 B | USA |
 |
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | USA |
 |
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | USA |
 |
LivaNova PLC
LIVN
|
-282 M | $ 61.31 | 2.01 % | $ 3.34 B |  Britain |
 |
ClearPoint Neuro
CLPT
|
3.85 M | $ 11.47 | 2.59 % | $ 325 M | USA |
 |
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
11 M | $ 0.62 | 2.05 % | $ 38.6 M | USA |
 |
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | USA |
 |
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | USA |
 |
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
IRIDEX Corporation
IRIX
|
-5.23 M | $ 1.03 | - | $ 17.4 M | USA |
 |
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | USA |
 |
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M |  Canada |
 |
OrthoPediatrics Corp.
KIDS
|
83.3 M | $ 15.27 | 1.39 % | $ 358 M | USA |
 |
Sintx Technologies
SINT
|
-898 K | $ 2.48 | 19.23 % | $ 6.88 M | USA |
 |
Butterfly Network
BFLY
|
-65.9 M | $ 5.4 | 12.63 % | $ 1.14 B | USA |
 |
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | USA |
 |
Stryker Corporation
SYK
|
11 B | $ 299.52 | -4.95 % | $ 114 B | USA |
 |
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
-511 M | $ 92.15 | 2.18 % | $ 12.5 B | USA |
 |
TransMedics Group
TMDX
|
-32.3 M | $ 99.41 | -1.37 % | $ 3.38 B | USA |
 |
Tandem Diabetes Care
TNDM
|
239 M | $ 19.28 | -1.25 % | $ 1.31 B | USA |
 |
CONMED Corporation
CNMD
|
802 M | $ 36.88 | 0.6 % | $ 1.14 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.18 B | $ 83.86 | -5.25 % | $ 2.91 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
-2.32 B | $ 84.39 | 1.07 % | $ 49.4 B | USA |
 |
LENSAR
LNSR
|
-10.2 M | $ 5.73 | 9.56 % | $ 68.5 M | USA |
 |
Pulmonx Corporation
LUNG
|
-31.6 M | $ 1.37 | 6.64 % | $ 55.7 M | USA |
 |
MiMedx Group
MDXG
|
-148 M | $ 3.64 | 8.33 % | $ 538 M | USA |
 |
Myomo
MYO
|
-4.79 M | $ 0.91 | 5.28 % | $ 38.1 M | USA |